Nephrology – Medxy AI

Hospital Acute Kidney Injury Strongly Linked to Long-Term Death, Dialysis, and CKD: Meta-Analysis of Matched-Control Studies

By MedXY 12/09/2025

A meta-analysis of 14 matched-control studies (n=1,058,109) finds that survivors of in-hospital AKI face higher long-term mortality, greater subsequent dialysis need, and elevated risk of CKD versus matched controls.

Cardiology Nephrology news

Lorundrostat Lowers 24‑Hour Systolic Blood Pressure in Treatment‑Resistant Hypertension but Raises Hyperkalemia Concerns

By MedXY 12/06/2025

A randomized, placebo‑controlled trial found lorundrostat reduced 24‑hour systolic BP by ~7–8 mm Hg versus placebo in patients with uncontrolled, treatment‑resistant hypertension; notable rates of marked hyperkalemia occurred only in active treatment groups.

Nephrology news

Pegcetacoplan Markedly Reduces Proteinuria in C3 Glomerulopathy and Immune‑Complex MPGN: Results from the VALIANT Phase 3 Trial

By MedXY 12/03/2025

In the phase 3 VALIANT trial, pegcetacoplan, a C3/C3b inhibitor, produced a large, rapid reduction in proteinuria versus placebo at 26 weeks in patients with C3 glomerulopathy or primary immune‑complex MPGN, with an acceptable short-term safety profile.

Cardiology Nephrology news

Comprehensive Summary of the FINEARTS-HF Trial Results on Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

By MedXY 12/03/2025

The FINEARTS-HF trial demonstrates finerenone’s efficacy and safety in reducing heart failure events, improving symptoms, and lowering new-onset diabetes risk, with consistent benefits across sex, ejection fraction ranges, frailty levels, and recent heart failure worsening.

Cardiology Nephrology news

Declining Kidney Function Often Precedes Heart Failure Hospitalization in HFrEF — Track eGFR Slopes, Not Just Thresholds

By MedXY 11/29/2025

In HFrEF, eGFR often falls progressively for up to a year before heart-failure hospitalization or death. Monitoring eGFR trajectories provides earlier risk signals than single cut-offs and may identify patients for closer decongestion or therapy optimization.

Cardiology Clinical Updates Diabetes & Endocrinology Nephrology news

Comprehensive Review of the EMPEROR-Preserved Trial: Efficacy and Outcomes of Empagliflozin in Heart Failure with Preserved Ejection Fraction

By MedXY 11/28/2025

This review comprehensively summarizes recent studies (2021–2024) from the EMPEROR-Preserved trial, highlighting empagliflozin’s consistent benefits on cardiovascular and renal outcomes, quality of life, and key clinical subgroups in HFpEF patients.

Cardiology Clinical Updates Nephrology news

Comprehensive Review of the EMPEROR-Preserved Trial: Efficacy and Safety of Empagliflozin in Heart Failure with Preserved Ejection Fraction

By MedXY 11/28/2025

This review synthesizes the pivotal EMPEROR-Preserved Trial results, highlighting empagliflozin's efficacy in reducing heart failure outcomes in patients with preserved ejection fraction.

Cardiology Nephrology news

SGLT2 Inhibitors Remain Protective Even After Severe eGFR Decline: Pooled Trial Analysis Across Cardio‑Renal‑Metabolic Populations

By MedXY 11/28/2025

A pooled analysis of five randomized trials (n=26,946) found that severe eGFR deterioration (<25 and <20 ml/min/1.73 m2) increased cardiovascular risk nearly twofold, but SGLT2 inhibitors reduced that risk and retained benefit regardless of subsequent severe kidney decline.

Diabetes & Endocrinology Nephrology news

Empagliflozin Protects the Kidney Across Clinical Spectra — Acute Dip Is Not a Dealbreaker

By MedXY 11/28/2025

An individual participant-level meta-analysis of 23,340 participants shows empagliflozin reduces acute and chronic kidney events, slows eGFR decline, and lowers kidney failure risk regardless of predicted acute eGFR dip, diabetes, heart failure, baseline eGFR, or albuminuria.

Cardiology Nephrology news

PAD4, NETs, and Inflammasome Activation: A New Mechanistic Link Between Diabetes and Cardiorenal Injury

By MedXY 11/28/2025

A translational study links hyperglycaemia-driven PAD4-dependent neutrophil extracellular trap (NET) formation and inflammasome activation to cardiac and renal inflammation, fibrosis, and heart failure in experimental diabetes—suggesting novel therapeutic targets.

Diabetes & Endocrinology Nephrology news

Balcinrenone plus Dapagliflozin Reduces Albuminuria in CKD: MIRO‑CKD Phase 2b Shows Dose‑Dependent Benefit with Acceptable Safety

By MedXY 11/28/2025

The MIRO‑CKD phase 2b trial found that adding the non‑steroidal MRA balcinrenone to dapagliflozin reduced albuminuria versus dapagliflozin alone in people with CKD, with dose‑dependent effects and modest hyperkalaemia rates over 12 weeks.

Critical Care Nephrology news

Biomarker-Guided Preventive Care Halves Risk of Moderate–Severe AKI After Major Surgery: Results from BigpAK-2

By MedXY 11/26/2025

In BigpAK-2, a multinational randomized trial, a KDIGO-based preventive bundle triggered by tubular stress biomarkers reduced moderate or severe acute kidney injury within 72 hours after major surgery (OR 0.57; NNT 12) without increasing adverse events.

Nephrology news Public Health

Unequal and Multisystem Mortality Risks After Tropical Cyclones: Renal, Injury, Infectious and Chronic Disease Burdens Across Nine Countries

By MedXY 11/21/2025

A multinational time-series study across nine countries found increased short-term mortality after tropical cyclones for multiple causes — highest for renal disease and injuries — with larger effects in deprived and cyclone-naïve communities and stronger associations with cyclone-related rainfall.

Nephrology news Pediatrics

Acute Kidney Injury in Extremely Preterm Infants Predicts Higher Risk of Death or Neurodevelopmental Impairment at Two Years

By MedXY 11/19/2025

Secondary analysis of the PENUT trial found that acute kidney injury (AKI) in infants born at 24–27 weeks’ gestation is independently associated with death or moderate to severe neurodevelopmental impairment at 22–26 months' corrected age.

Nephrology news Public Health

Temporary Inpatient Hemodialysis Access for Uninsured Patients Is Associated with Shorter Hospital Stays in a County Safety-Net System

By MedXY 11/19/2025

A Los Angeles County quality-improvement study found that regulatory approval allowing an inpatient hemodialysis unit to provide transitional outpatient dialysis to uninsured patients initiating hemodialysis was associated with a substantial, sustained reduction in hospital length of stay.

Nephrology news

Community Health Workers Reduce Interdialytic Weight Gain and Improve Engagement Among Hispanic/Latino Hemodialysis Patients: Results from the Navigate‑Kidney RCT

By MedXY 11/18/2025

A randomized trial found that a culturally tailored community health worker (CHW) intervention modestly reduced interdialytic weight gain, improved dialysis adherence, and increased patient activation among Hispanic and Latino adults receiving in‑center hemodialysis.

Internal Medicine Nephrology news

The Vanishing Female Survival Advantage in Stage 5 CKD: Higher Mortality and Lower Receipt of Kidney Replacement Therapy Among Women

By MedXY 11/17/2025

In a population-based Alberta cohort, women with incident stage 5 CKD lost the usual female survival advantage: younger women had substantially higher excess mortality than men and were less likely to receive transplants or dialysis, independent of comorbidity.

Internal Medicine Nephrology news

Clinical Decision Support Tool May Improve ACEI and ARB Use in CKD

By MedXY 11/14/2025

A personalized clinical decision support tool increased 30‑day reinitiation of ACE inhibitors or ARBs from 13% to 18% among veterans with CKD; benefits were modest and limited by population and implementation factors.

Nephrology news

Albuminuria Reduction and GFR Total-Slope Strongly Predict Kidney Failure: Surrogate Endpoints in CKD Trials

By MedXY 11/13/2025

Large individual-patient meta-analyses show that 6-month albuminuria reduction and 3-year total GFR slope predict kidney failure across CKD populations—supporting their use as surrogate endpoints in randomized trials with caveats for chronic slope and disease severity.

Nephrology news

Global CKD Now Affects 788 Million Adults (1990–2023): Rising Prevalence, Growing Mortality, and a Major Cardiovascular Risk

By MedXY 11/11/2025

The GBD 2023 analysis estimates 788 million adults living with chronic kidney disease in 2023, rising since 1990, with CKD a top-10 cause of death and a major contributor to cardiovascular mortality. Urgent action on screening, prevention, and treatment is needed.